Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Anixa Biosciences Inc ANIX

Healthcare Biotechnology
Anixa Biosciences, Inc. is a biotechnology company developing vaccines and therapies that are focused on critical unmet needs in oncology. Its segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Other. Its vaccine programs include the development of a preventative vaccine against triple negative breast cancer (TNBC), the most lethal form of breast cancer, as well as other forms of breast cancer and the development of a preventative vaccine against ovarian cancer. Its therapeutics programs include the development of a chimeric endocrine receptor T cell therapy, a novel form of chimeric antigen receptor T cell (CAR-T) technology, initially focused on treating ovarian cancer, which is being developed by its subsidiary, Certainty Therapeutics, Inc. (Certainty). Certainty is developing immuno-therapy drugs against cancer. The Company’s vaccine portfolio consists of technology focused on the immunization against specific retired proteins.


NDAQ:ANIX - Post by User

Anixa Biosciences Inc
<< Previous
 Bullboard Posts
User Avatar Image
(6)
•••
Post by Shanemorg58on Dec 19, 2022 11:33am
81 Views
Post# 35179736

Awesome to hear from the CEO!

Awesome to hear from the CEO!Interesting video with Anixa's CEO. Apparently the success of Merck's Keytruda in combination with Moderna's mRNA vaccine has application for their lead candidate as well. I found this on their San Antonio poster for future direction."Add cohort to test vaccine adjuvant therapy with checkpoint inhibitor pembrolizumab" As you might know, Pembrolizumab is just another name for Keytruda... so looks like they want to do a combination trial of their breast cancer vaccine with Keytruda too. If that combination trial reduced recurrance by 44%, could be very interesting to see what Anixa's vaccine achieves in combination for breast cancer.... big stuff happening!!
https://www.youtube.com/watch?v=2z0692FgnOM&t=41s&ab_channel=AnixaBiosciences%2CInc 
<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities